Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

222 Press Releases
DateTitleCompany
17 Dec 14 Dabigatran etexilate (Pradaxa®) green-lighted by NICE for treating and preventing the recurrence of deep vein thrombosis and pulmonary embolism. Boehringer Ingelheim Limited,
Published by
Business Wire
19 Nov 14 New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans Boehringer Ingelheim,
Published by
Business Wire
16 Oct 14 Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis Boehringer Ingelheim,
Published by
Business Wire
13 Oct 14 Boehringer Ingelheim Buoyed as Two Medicines Receive Scottish Medicines Consortium (SMC) Green Light for Use within the NHS Boehringer Ingelheim,
Published by
Business Wire
01 Oct 14 Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care Boehringer Ingelheim
27 Sep 14 Afatinib? demonstrates superior progression-free survival compared to erlotinib in head-to-head Phase III trial in patients with advanced squamous cell carcinoma of the lung after failure of platinum based chemotherapy Boehringer Ingelheim,
Published by
Business Wire
19 Sep 14 Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Boehringer Ingelheim Named to Working Mother’s “100 Best Companies for Working Mothers” List Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study Boehringer Ingelheim,
Published by
Business Wire
09 Sep 14 TONADO™ study shows further lung function and quality of life benefits with tiotropium + olodaterol Respimat® fixed dose combination in COPD Boehringer Ingelheim
09 Sep 14 Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting Boehringer Ingelheim, Eli Lilly,
Published by
PharmiWeb.com
25 Aug 14 New Pradaxa® data to be presented at the ESC Congress 2014 Boehringer Ingelheim,
Published by
Business Wire
15 Jul 14 Pradaxa® (dabigatran etexilate) now available in the UK for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrence Boehringer Ingelheim
16 Jun 14 New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia Boehringer Ingelheim,
Published by
Business Wire
15 Jun 14 Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition Boehringer Ingelheim,
Published by
Business Wire
06 Jun 14 ADDING MULTIMEDIA: Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
06 Jun 14 Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
05 Jun 14 European Medicines Agency (EMA) accepts accelerated marketing authorisation application for nintedanib in IPF Boehringer Ingelheim
05 Jun 14 EMA accepts marketing authorisation application for nintedanib* in IPF Boehringer Ingelheim,
Published by
Business Wire
02 Jun 14 New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy Boehringer Ingelheim,
Published by
Business Wire
27 May 14 IPF Phase III trial results published in New England Journal of Medicine (NEJM) show nintedanib* slows disease progression by approximately 50% compared with placebo Boehringer Ingelheim
23 May 14 Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin) Boehringer Ingelheim,
Published by
Business Wire
21 May 14 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone Boehringer Ingelheim,
Published by
Business Wire
15 May 14 New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer Boehringer Ingelheim
15 May 14 Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer, compared to chemotherapy Boehringer Ingelheim
30 Apr 14 Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference Boehringer Ingelheim,
Published by
Business Wire
29 Apr 14 Boehringer Ingelheim and AmeriCares Partner in New Extension of Product Donations Program for the Uninsured Boehringer Ingelheim Pharmaceuticals Inc.,
Published by
Business Wire
28 Apr 14 Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots Boehringer Ingelheim,
Published by
Business Wire
08 Apr 14 FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) Boehringer Ingelheim,
Published by
Business Wire
06 Mar 14 Pradaxa® (dabigatran etexilate) now approved in over 100 countries for stroke prevention in atrial fibrillation Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.